	US 12,252,699 B2
	Method for generating t-cells compatible for allogenic transplantation
Laurent Poirot, Paris (FR); David Sourdive, Levallois-Perret (FR); Philippe Duchateau, Dravell (FR); and Jean-Pierre Cabaniols, Saint Lau la Foret (FR)
Assigned to CELLECTIS, Paris (FR)
Filed by CELLECTIS, Paris (FR)
Filed on Oct. 4, 2023, as Appl. No. 18/480,890.
Application 18/480,890 is a division of application No. 16/138,908, filed on Sep. 21, 2018, granted, now 11,820,996.
Application 16/138,908 is a division of application No. 15/123,974, abandoned, previously published as PCT/EP2015/055097, filed on Mar. 11, 2015.
Claims priority of application No. PA201470119 (DK), filed on Mar. 11, 2014.
Prior Publication US 2024/0026376 A1, Jan. 25, 2024
Int. Cl. C12N 15/85 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01); C12N 5/0783 (2010.01); C12N 15/113 (2010.01); C12N 15/90 (2006.01)

CPC C12N 15/85 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); C07K 14/70503 (2013.01); C07K 14/70539 (2013.01); C12N 5/0636 (2013.01); C12N 15/1138 (2013.01); C12N 15/907 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01)]

12 Claims

1. A method for preparing engineered human T-cells expressing a Chimeric Antigen Receptor (CAR) that have lost surface expression of HLA-A, HLA-B, and HLA-C comprising:

a) providing a population of human T-cells comprising a CAR;

b) introducing into said human T-cells a rare-cutting endonuclease able to selectively inactivate the gene encoding B2M,

wherein said rare-cutting endonuclease is a TALE-nuclease encoded by a polynucleotide having at least 90% identity with SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:87, or SEQ ID NO:88; and

c) cleaving the B2M gene with said rare-cutting endonuclease in said human T-cells to induce loss of surface expression of B2M, HLA-A, HLA-B, and HLA-C.